PH22989A - Pharmaceutical dosage unit - Google Patents

Pharmaceutical dosage unit

Info

Publication number
PH22989A
PH22989A PH34074A PH34074A PH22989A PH 22989 A PH22989 A PH 22989A PH 34074 A PH34074 A PH 34074A PH 34074 A PH34074 A PH 34074A PH 22989 A PH22989 A PH 22989A
Authority
PH
Philippines
Prior art keywords
dosage unit
pharmaceutical dosage
pharmaceutical
unit
dosage
Prior art date
Application number
PH34074A
Other languages
English (en)
Inventor
Thomas Robert Malefyt
Chester Allen Meyers
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of PH22989A publication Critical patent/PH22989A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PH34074A 1985-07-29 1986-07-28 Pharmaceutical dosage unit PH22989A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75978585A 1985-07-29 1985-07-29

Publications (1)

Publication Number Publication Date
PH22989A true PH22989A (en) 1989-02-24

Family

ID=25056946

Family Applications (1)

Application Number Title Priority Date Filing Date
PH34074A PH22989A (en) 1985-07-29 1986-07-28 Pharmaceutical dosage unit

Country Status (15)

Country Link
EP (1) EP0211592A3 (fi)
JP (1) JPS6236332A (fi)
KR (1) KR870000918A (fi)
CN (1) CN86105526A (fi)
AU (1) AU593566B2 (fi)
DK (1) DK352686A (fi)
ES (1) ES2000743A6 (fi)
FI (1) FI863077A (fi)
GR (1) GR861961B (fi)
HU (1) HU198264B (fi)
NO (1) NO863029L (fi)
PH (1) PH22989A (fi)
PT (1) PT83075B (fi)
ZA (1) ZA865652B (fi)
ZW (1) ZW14486A1 (fi)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
AT391812B (de) * 1985-05-28 1990-12-10 Wellcome Found Verfahren zur herstellung einer parenteralen t-pa-loesung
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
DE3822557C2 (de) * 1987-07-10 1998-07-02 Ciba Geigy Ag Arzneimittel, enthaltend Somatostatine
US4929560A (en) * 1988-02-03 1990-05-29 Damon Biotech, Inc. Recovery of tissue plasminogen activator
DE3806562A1 (de) * 1988-03-01 1989-09-14 Alpha Therapeutic Gmbh Zweikammerspritze mit einer fuellung aus aktivitaetsempfindlichem humanen protein als wirkstoff
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
GB8814604D0 (en) * 1988-06-20 1988-07-27 Wellcome Found Medicaments
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
AU6470590A (en) 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
DE3942141A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh K2p pro-stabilisierung
DE3942144A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von k1k2p pro
DE3942145A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa-solubilisierung
DE3942143A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh T-pa pro stabilisierung
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
US5366730A (en) * 1989-12-20 1994-11-22 Boehringer Mannheim Gmbh Stabilized compositions having human tissue type plasminogen activator enzymatic activity
CA2107476C (en) * 1991-04-16 2007-12-18 Martin Ulrich Pharmaceutical packaging unit containing plasminogen activators for multiple bolus administration
US5272076A (en) * 1991-06-13 1993-12-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
US5747447A (en) * 1992-04-30 1998-05-05 Cor Therapeutics Stable polypeptide composition
AU664469B2 (en) * 1992-06-03 1995-11-16 Genentech Inc. Tissue plasminogen activator glycosylation variants with improved therapeutic properties
ES2479515T3 (es) 2004-07-26 2014-07-24 Merz Pharma Gmbh & Co. Kgaa Composición terapéutica con una neurotoxina botulínica
KR102194891B1 (ko) 2020-07-08 2020-12-28 대상 주식회사 계란프라이 조리장치

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8003402A (nl) * 1980-06-11 1982-01-04 Leuven Res & Dev Vzw Nieuwe plasminogeen-activator en farmaceutisch preparaat met trombolytische werking.
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
AT391812B (de) * 1985-05-28 1990-12-10 Wellcome Found Verfahren zur herstellung einer parenteralen t-pa-loesung
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
EP0211592A3 (en) 1988-03-02
DK352686A (da) 1987-01-30
FI863077A (fi) 1987-01-30
KR870000918A (ko) 1987-03-10
NO863029L (no) 1987-01-30
DK352686D0 (da) 1986-07-24
HU198264B (en) 1989-09-28
PT83075B (en) 1988-07-13
NO863029D0 (no) 1986-07-28
HUT42953A (en) 1987-09-28
CN86105526A (zh) 1987-02-04
ZW14486A1 (en) 1986-10-22
EP0211592A2 (en) 1987-02-25
AU6064786A (en) 1987-02-05
GR861961B (en) 1986-11-26
FI863077A0 (fi) 1986-07-28
AU593566B2 (en) 1990-02-15
ES2000743A6 (es) 1988-03-16
ZA865652B (en) 1987-11-25
JPS6236332A (ja) 1987-02-17
PT83075A (en) 1986-08-01

Similar Documents

Publication Publication Date Title
ZW14486A1 (en) Pharmaceutical dosage unit
ZA868249B (en) Pharmaceutical preparation
GB2183217B (en) Dosage device
GB8608149D0 (en) Furazolidine dosage form
GB8601389D0 (en) Treating pharmaceutical dosage forms
ZA8667B (en) Pharmaceutical preparation
GR861421B (en) Pharmaceutical tablet
GB2174004B (en) Pharmaceutical tablet preparations
GB2171305B (en) Pharmaceutical combinations
IE861995L (en) Pharmaceutical dosage unit
GB8521342D0 (en) Medicament
GB8603031D0 (en) Pharmaceutical formulations
AU93542S (en) Pharmaceutical tablet
AU93541S (en) Pharmaceutical tablet
ZA87111B (en) Pharmaceutical dosage form
GB8529161D0 (en) Pharmaceutical compounds
GB8515665D0 (en) Pharmaceutical compounds
GB8509889D0 (en) Pharmaceutical mixtures
GB8529502D0 (en) Pharmaceutical mixtures
GB8522761D0 (en) Pharmaceutical preparation
GB8502917D0 (en) Pharmaceutical formulation
GB8519741D0 (en) Pharmaceutical formulation
GB8524811D0 (en) Pharmaceutical formulation
GB8530794D0 (en) Pharmaceutical formulation
AU95290S (en) Medicine dosage spoon